Femasys Gets Notice of Allowance for New US FemaSeed Patent

MT Newswires Live

01/17

Femasys (FEMY) said Thursday that the US Patent and Trademark Office has granted a notice of allowance for an application covering the use of FemaSeed for female infertility treatment.

The company said it expects the patent to last until at least 2044.

Femasys added that it plans to file more patent applications to protect FemaSeed, FemBloc permanent birth control, and other diagnostic products, such as FemVue, FemCath, and FemCerv.

Shares of Femasys rose past 4% in recent trading activity.

Price: 1.11, Change: +0.05, Percent Change: +4.72

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2504836914"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2504836914\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2504836914?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-17 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504836914","market":"sg","top_or_hot":-1,"title":"Femasys Gets Notice of Allowance for New US FemaSeed Patent","media":"MT Newswires Live","content":"<html><body><p> Femasys (FEMY) said Thursday that the US Patent and Trademark Office has granted a notice of allowance for an application covering the use of FemaSeed for female infertility treatment.</p><p>The company said it expects the patent to last until at least 2044.</p><p>Femasys added that it plans to file more patent applications to protect FemaSeed, FemBloc permanent birth control, and other diagnostic products, such as FemVue, FemCath, and FemCerv.</p><p>Shares of Femasys rose past 4% in recent trading activity.</p><p>Price: 1.11, Change: +0.05, Percent Change: +4.72</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Femasys Gets Notice of Allowance for New US FemaSeed Patent</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFemasys Gets Notice of Allowance for New US FemaSeed Patent\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-01-17 00:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Femasys (FEMY) said Thursday that the US Patent and Trademark Office has granted a notice of allowance for an application covering the use of FemaSeed for female infertility treatment.</p><p>The company said it expects the patent to last until at least 2044.</p><p>Femasys added that it plans to file more patent applications to protect FemaSeed, FemBloc permanent birth control, and other diagnostic products, such as FemVue, FemCath, and FemCerv.</p><p>Shares of Femasys rose past 4% in recent trading activity.</p><p>Price: 1.11, Change: +0.05, Percent Change: +4.72</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FEMY","symbol_name":"Femasys Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2504836914","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504836914","pubTimestamp":1737043698,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Femasys  said Thursday that the US Patent and Trademark Office has granted a notice of allowance for an application covering the use of FemaSeed for female infertility treatment.The company said it expects the patent to last until at least 2044.Femasys added that it plans to file more patent applications to protect FemaSeed, FemBloc permanent birth control, and other diagnostic products, such as FemVue, FemCath, and FemCerv.Shares of Femasys rose past 4% in recent trading activity.Price: 1.11, Change: +0.05, Percent Change: +4.72","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FEMY":"Femasys Inc","BK4539":"次新股","BK4584":"避孕概念","BK4082":"医疗保健设备"},"translate_title":"Femasys获得美国FemaSeed新专利许可通知","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FEMY":1},"content_text":"Femasys (FEMY) said Thursday that the US Patent and Trademark Office has granted a notice of allowance for an application covering the use of FemaSeed for female infertility treatment.The company said it expects the patent to last until at least 2044.Femasys added that it plans to file more patent applications to protect FemaSeed, FemBloc permanent birth control, and other diagnostic products, such as FemVue, FemCath, and FemCerv.Shares of Femasys rose past 4% in recent trading activity.Price: 1.11, Change: +0.05, Percent Change: +4.72","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}